TIDMSKP TIDMTTM TIDMTTM
RNS Number : 0822X
Skyepharma PLC
26 August 2015
2015 Interim Results
H1 revenues up 19% and on track to deliver substantial growth
for the full year
LONDON, ENGLAND, 26 August 2015 - Skyepharma PLC (LSE: SKP), the
expert oral and inhalation drug development company, today reports
its unaudited interim results for the six months ended 30 June
2015.
Financial Highlights
-- Revenues up 19% at GBP40.8m (H1 2014: GBP34.4m)
-- Revenues excluding milestones up 51% at GBP40.7m (H1 2014:
GBP26.9m) driven by growth in revenues from flutiform(R) ,
EXPAREL(R) , GSK Ellipta(R) products and Solaraze(R)
-- Operating profit GBP12.5m (H1 2014: GBP13.2m)
-- Operating profit excluding milestones up 118% to GBP12.4m (H1 2014: GBP5.7m)
-- Profit after tax GBP9.1m (H1 2014: loss of GBP17.7m)
-- Pre-exceptional profit after tax up 17% to GBP9.1m (H1 2014: GBP7.8m)
-- Basic earnings per share 8.7 pence (H1 2014: loss per share 27.0 pence)
-- Cash and cash equivalents of GBP27.6m at 30 June 2015 (31
December 2014: GBP32.4m) after early repayments of secured debt at
a cost of GBP11.8m, saving GBP1.0m in total future financing
charges and leaving net cash of GBP20.9m (31 December 2014:
GBP15.0m)
-- Further strengthening of the balance sheet with early
repayment of expensive secured debt and signing of a Revolving
Credit Facility (RCF)
-- Progress is being made with investment in additional
flutiform(R) manufacturing capacity and product supply revenues are
expected to be ahead of the Board's previous expectations for 2015.
As a result, after allowing for the likely shift of the next
EXPAREL(R) sales milestone into 2016, underlying trading for the
year is expected to be ahead of previous expectations
Operational Highlights
-- 65% of revenues derived from products launched since March 2012 (H1 2014: 62%)
-- Sustained growth of flutiform(R) driving royalty and product
supply revenues and profitability
-- In-market sales of flutiform(R) up 129% from H1 2014
-- Sales by Pacira of EXPAREL(R) up 42% from H1 2014
-- Sales by GSK of the royalty-generating Ellipta(R) range of
products of GBP123m in H1 2015 compared with GBP19m in H1 2014
following additional approvals and launches of Breo(R) /Relvar(R)
Ellipta(R) , Anoro(R) Ellipta(R) and Incruse(R) Ellipta(R)
-- Royalties from Solaraze(R) and its authorised generic in the
U.S. are significantly ahead of expectations due to a temporary
market situation involving manufacturing issues at a competitor
-- Continued progress with developing the Group's inhalation and oral pipeline
Commenting on the results, Peter Grant, Chief Executive Officer,
said:
"With a strong start to the year, Skyepharma is on track to
deliver substantial growth in revenues in 2015, driven by products
launched since March 2012. flutiform continues to gain momentum as
its benefits are recognised by clinicians and patients in 30
countries around the world. Since H1 2014 we have seen further
increases in revenues of EXPAREL and the GSK Ellipta range of
products incorporating some of our proprietary technologies.
"We are on course to deliver a number of key objectives we set
out at the start of the year, including growing revenues from
approved products, scaling up production capacity for flutiform,
further reducing our financing costs, improving balance sheet
flexibility and progressing our internal R&D programmes where
the net investment is weighted towards the second half of the year.
We look forward to the rest of 2015 with confidence."
A PDF version of the results presentation has been published on
the Company's website and a webcast of the analysts' results
presentation will be available shortly.
- Ends -
For further information please contact:
Skyepharma PLC
Peter Grant, Chief Executive Officer
Andrew Derodra, Chief Financial Officer +44 (0)20 7881 0524
Jonathan Birt, Investor and Media Relations +44 (0)7860 361746
N+1 Singer
Shaun Dobson/Jen Boorer +44 (0)20 7496 3000
FTI Consulting
Julia Phillips/Rob Winder/Natalie Garland-Collins +44 (0)20 3727 1000
About Skyepharma PLC
Skyepharma combines proven scientific expertise with validated
proprietary technologies to develop innovative oral and inhalation
pharmaceutical products. The Group's licenses cover 16 approved
inhalation, oral, topical and injectable products, which generate
milestones, recurring royalties, and in some cases, product supply
revenues. The Group also earns milestones and contract development
revenues from new product developments. Products developed by
Skyepharma are marketed by some of the world's most respected
pharmaceutical companies. For more information, visit
www.skyepharma.com
OPERATING REVIEW
Summary
Skyepharma has had a strong start to 2015, with continued
momentum in revenues from the key growth drivers of products
launched since March 2012 and increased planned investment in the
development pipeline to deliver additional growth in the
medium-term. Key events in the first half of the year included:
-- Robust financial and operating cash performance for the half
year, with an operating profit of GBP12.5 million, a closing cash
balance of GBP27.6 million and net cash increasing to GBP20.9
million from GBP15 million at 31 December 2014
-- A first full six months of revenues from flutiform(R) in all
the major European markets, following the launch in Spain in
December 2014, and in Japan, where the 120-puff version was also
launched in December 2014. Growing demand for flutiform(R) has
driven an increased gross profit from the supply chain and the
Group has continued with the previously-announced capital
investments to provide capacity to meet forecast requirements
-- Launch of flutiform(R) in Malaysia, the Philippines, Kuwait
and the UAE, bringing the total number of markets where
flutiform(R) is available to 30. As at 30 June 2015, flutiform(R)
had been approved in a further 6 countries and was under review in
another 14; since then an additional approval has also been
received in Lebanon
-- Initiatives to expand the flutiform(R) opportunity continued
with further development of the breath-actuated version for
Mundipharma, completion of recruitment for the European COPD study,
ongoing recruitment for clinical trials for Asia Pacific (COPD) and
further preparations for trials in China for asthma. Mundipharma
has withdrawn the European paediatric filing and is seeking a
meeting with the UK Medicine and Healthcare Regulatory Products
Agency (MHRA) to agree a way forward. Given the size of the
paediatric market this is not expected to have a material effect on
potential sales of flutiform(R)
-- Higher receipts from the 3 percent share of net sales of
EXPAREL(R) where Pacira has reported net sales of U.S. $112.9
million in the first half of 2015, up 42 percent from U.S. $79.3
million in H1 2014
-- Substantial increase in royalties from GSK's Ellipta(R) range
of inhalation products which utilise Skyepharma technology, with
GSK reporting H1 net sales of GBP123 million, compared with GBP19
million in H1 2014, following launches in Europe, Japan and the
U.S.
-- Higher than expected contribution from U.S. sales of
Solaraze(R) and its authorised generic due to a temporary market
opportunity related to manufacturing issues at a competitor
-- Continued investment in self-funded pipeline development including:
-- initial formulation and preparation for pre-clinical work for SKP-2075 in COPD
-- commencement of feasibility work as previously disclosed on a
novel inhalation product combining known chemical entities intended
for early partnering (SKP-2076)
-- further work to optimise the new gastro-retentive oral drug delivery technology Soctec(TM)
-- The Group is in discussion with potential partners to fund
further development of SKP-1052, the novel oral product aimed at
the prevention of severe nocturnal hypoglycaemia
-- Further improvements in balance sheet strength and flexibility:
-- early redemption and termination of remaining CRC Finance
facility and the secured Swiss loan; the only borrowings remaining
are the Swiss mortgages
-- GBP25 million, five-year unsecured multi-currency Revolving
Credit Facility (RCF) signed in April with Barclays Bank PLC, with
an accordion option of GBP10 million which would extend the RCF to
GBP35 million
Outlook
The Board expects continued substantial growth in revenues in
2015 compared with 2014, due to ongoing momentum from the products
launched since March 2012, especially flutiform(R), EXPAREL(R) and
the GSK Ellipta(R) -range of products, as well as the exceptional
performance of Solaraze(R) in the U.S. in H1 2015. Based on current
forecasts by analysts who follow Pacira, the next sales milestone
of U.S. $8.0 million (GBP5.1 million) receivable by Skyepharma,
which is due when annual net sales of EXPAREL(R) (on a cash
received basis) reach U.S. $250 million, is expected to be
triggered in 2016.
The Directors expect that flutiform(R) product supply revenues
for 2015 will be ahead of the Board's previous expectations given
recent growth in customer demand forecasts. As a result, after
allowing for the likely shift of the EXPAREL(R) milestone into
2016, the Directors believe that underlying trading for the year
will be ahead of previous expectations.
A first sales milestone of EUR10 million (GBP7.1 million) is due
from Mundipharma when its net sales of flutiform(R) reach EUR100
million (GBP70.1 million) in a calendar year. If this is achieved
in 2015, a portion of the milestone would be recorded in revenues
in the year through release of deferred income, although it is not
anticipated that any cash will be received as it will be used to
satisfy a large part of the balance of Mundipharma's right to
recover up to EUR25 million (GBP17.6 million) of previous
development costs.
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
In line with the estimate provided earlier in the year, net
investment in research and development for 2015 is forecast to be
around GBP10 million, depending on exchange rates. This includes
continuing investment in a number of novel oral drug delivery
platform technologies including Soctec(TM), SKP-2075, the novel
potential anti-inflammatory treatment for COPD and SKP-2076, a
novel inhalation product based on known chemical entities, where
feasibility work has been started with a view to early partnering
for further development.
As announced in March 2015, in response to increasing
medium-term demand forecasts, substantial capital investment is
being made to achieve a faster step up in planned manufacturing
capacity of flutiform(R) . As a result, capital expenditure on
flutiform(R) in 2015 remains on track to total approximately GBP7
million to GBP8 million.
Total capital expenditure in 2015 is also forecast to be
approximately GBP8 million to GBP9 million, including support for
R&D activities and IT improvement projects.
Corporate, sales and marketing and share based payment charges
are expected to grow modestly overall compared with 2014.
The Board is confident that the Group has good prospects for
growth from the 16 approved products already being marketed and is
looking forward to adding further potential from Skyepharma's
proven inhalation and oral drug development capabilities.
Financial Highlights
Revenues in the first half of 2015 were GBP40.8 million, up 19
percent from GBP34.4 million in H1 2014. This was driven by strong
growth in flutiform(R) royalty and product supply, the Group's
share of higher net sales of EXPAREL(R), royalties from increased
sales of the GSK Ellipta(R) products and higher than expected
royalties from Solaraze(R) in the U.S. The growth was achieved
despite the inclusion of GBP7.5 million of milestones in H1 2014
relating to the achievement of the first sales-related milestone
for EXPAREL(R) and the commercial launch of flutiform(R) in France,
compared with GBP0.1 million in H1 2015. Revenues excluding
milestones were GBP40.7 million, 51 percent higher than H1 2014
(GBP26.9 million).
By the end of June 2015, the Group was earning revenues from 16
(H1 2014: 15) approved products which together generated GBP35.7
million of royalty, share of sales and product supply revenues (H1
2014: GBP22.5 million) of which GBP26.5 million (H1 2014: GBP21.8
million) related to eight products launched in key markets since
March 2012. Recurring revenues (royalties, product supply and share
of sales) comprised 87 percent of total revenues (H1 2014: 65
percent). Total revenues from products launched since March 2012
represented 65 percent of total revenues in the period (H1 2014: 62
percent).
flutiform(R) generated GBP2.5 million of contract development
revenue in the first half of 2015 (H1 2014: GBP1.3 million).
Cost of sales increased to GBP18.9 million (H1 2014: GBP13.2
million) due to higher flutiform(R) and other product supplies.
Net operating costs increased to GBP9.4 million in 2015 (H1
2014: GBP8.0 million), with GBP1.0 million higher gross investment
in research and development projects (partly offset by GBP0.8
million higher contract development revenues) and a small increase
in corporate costs.
Operating profit is down slightly to GBP12.5 million from
GBP13.2 million in H1 2014 due to the effect of the prior period
milestones (H1 2014: GBP7.5 million). Excluding milestones,
underlying operating profit was up 118 percent to GBP12.4 million
(H1 2014: GBP5.7 million), illustrating strengthening growth in
recurring revenues.
Profit after tax was GBP9.1 million (H1 2014: loss of GBP17.7
million). The prior year included an exceptional finance charge of
GBP25.5 million reflecting the settlement of the bonds and related
transaction costs. Basic earnings per share were 8.7 pence (H1
2014: loss per share 27.0 pence), whilst diluted earnings per share
were 8.6 pence (H1 2014: loss per share of 27.0 pence).
Cash flows reflect GBP0.1 million of milestone receipts (H1
2014: GBP2.7 million). EBITDA (earnings before interest, tax,
depreciation and amortisation) totalled GBP14.2 million (H1 2014:
GBP14.6 million) and represented 35 percent of revenues (H1 2014:
42 percent of revenues, which benefited from higher milestone
revenues with no related cost of sales).
As at 30 June 2015, the Group had net cash of GBP20.9 million
(31 December 2014: net cash GBP15.0 million). Gross debt amounted
to GBP6.7 million and the Group's cash was GBP27.6 million, down
GBP4.8 million since 31 December 2014 as a result of paying off
costly secured debt. Cash was utilised for the early redemption of
the remaining U.S. Dollar balance of the CRC Finance facility on 27
February 2015 at a cost of GBP10.5 million, saving GBP0.9 million
in future finance charges, and the early repayment of a secured
Swiss amortising loan on 30 June 2015 at a cost of GBP1.2 million,
saving GBP0.1 million in future finance charges.
Operational Highlights
flutiform(R)
flutiform(R), the fixed dose combination of fluticasone, an
inhaled corticosteroid ("ICS"), and formoterol, a long-acting beta
agonist ("LABA") in a pressurised metered dose inhaler, continues
to be an important value driver for the Group. As of 25 August
2015, flutiform(R) has been approved in 37 countries and launched
in 30, including recent launches in Malaysia, the Philippines,
Kuwait and the UAE.
In-market sales of flutiform(R) for the six months ended 30 June
2015 totalled EUR65.1 million (GBP47.2 million) (H1 2014: EUR28.4
million (GBP23.3 million)). In Q2 2015, total in-market sales of
flutiform(R) were EUR34.5 million (GBP24.6 million), up 13 percent
from EUR30.6 million (GBP22.5 million) in Q1 2015. Note: in-market
sales are internal calculations using IMS Health (IMS) data based
on sales to pharmacies and excluding certain minor countries not
covered by IMS. In-market sales are not the same as sales to
wholesalers on which royalties are payable to the Group.
In Japan, where the 120-puff version was launched on 1 December
2014 following the launch of the 56-puff version in November 2013,
in-market sales for the six months ended 30 June 2015 (included in
the above sales) totalled EUR18.1 million (GBP13.1 million) (H1
2014: EUR4.5 million (GBP3.7 million)). In Q2 2015, total in-market
sales of flutiform(R) were EUR10.0 million (GBP7.1 million), up 23
percent from EUR8.1 million (GBP6.0 million) in Q1 2015. Kyorin has
announced a target of JPY 10.3 billion (GBP53.4 million) for gross
sales of flutiform(R) in Japan for the year ending 31 March 2016
excluding gross to net discounts.
Minoru Hogawa, President & CEO, Kyorin Holdings Inc,
commented, "flutiform is an important new product for Kyorin. We
are greatly encouraged by the reception for the 120-puff version
from patients and clinicians in Japan, which increases our
confidence that we can continue to achieve significant growth in
the current year to March 2016."
In-market sales trends for flutiform(R) have been as
follows:
EUR'm 2012 2013 Q1 '14 Q2 '14 Q3 '14 Q4 '14 Q1 '15 Q2 '15
--------------------- ----- ----- ------- ------- ------- ------- ------- -------
E.U./ROW
(excluding America
and Japan) 0.8 17.9 10.5 13.4 14.6 18.5 22.5 24.5
--------------------- ----- ----- ------- ------- ------- ------- ------- -------
Japan - 1.5 1.6 2.9 3.3 7.4 8.1 10.0
--------------------- ----- ----- ------- ------- ------- ------- ------- -------
Total 0.8 19.4 12.1 16.3 17.9 25.9 30.6 34.5
--------------------- ----- ----- ------- ------- ------- ------- ------- -------
Quarter on quarter
total growth 28% 34% 10% 45% 18% 13%
--------------------- ----- ----- ------- ------- ------- ------- ------- -------
Mundipharma, the Group's licensee in Europe and most other
territories outside Japan and the Americas, is seeking to extend
the reach of flutiform(R) both geographically and through line
extensions. As at 30 June 2015, applications for marketing
authorisations were under review in 13 countries in the Middle
East, Far East and Africa.
In May, Mundipharma completed recruitment of over 1,700 patients
for its European clinical study of flutiform(R) for COPD. This
study is a 52-week multi-centre, randomised, double-blind,
active-controlled, parallel-group study. Mundipharma is also
undertaking clinical trials in Asia-Pacific (including China) for
COPD and in China for asthma.
In June, notwithstanding the successful conclusion of a Phase
III study into the efficacy and tolerability of flutiform(R) for
asthma in children aged 5 to 11 which met its primary endpoints
(p<0.001), Mundipharma received notification from the MHRA that
the ongoing European regulatory procedure to obtain a paediatric
indication could not be satisfactorily concluded in the required
timeframe. Mundipharma has withdrawn its submission and plans to
meet with the MHRA to ascertain what further information would be
required to enable potential resubmission of the file. The total
European paediatric market is less than two percent of the total
market for ICS/LABA combination products and this outcome is not
expected to have a material impact on sales of flutiform(R) .
Antony Mattessich, Managing Director, Mundipharma International,
said, "The unique combination of the fastest onset LABA approved
for asthma with a potent ICS and patient-friendly device is helping
to drive acceptance of flutiform across Europe, and we look forward
to increasing our market share as well as continuing to bring the
product to patients in new markets in the Asia Pacific and MENA
(Middle East and North Africa) regions."
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
Skyepharma continues to support Mundipharma in its development
of a novel breath-actuated version of flutiform(R), where the
flutiform(R) pMDI press-and-breathe actuator is replaced by
Mundipharma's breath-actuated device. If approved and launched,
Skyepharma would be eligible for revenues from royalties,
milestones and filled canister supply on a similar basis to
flutiform(R).
In 2014, Sanofi, the Group's licensee in Latin America, received
marketing approval for flutiform(R) in Argentina. A new drug
application remains under review in Colombia and further
applications are being prepared. The potential for launching in the
region continues to be under discussion with Sanofi.
EXPAREL(R)
In July 2015, Pacira Pharmaceuticals, Inc. ("Pacira"), reported
first half 2015 net sales of EXPAREL(R) (bupivacaine liposome
injectable suspension), an injectable product for single-dose
administration into the surgical site to produce postsurgical
analgesia, of U.S. $112.9 million, compared with U.S. $79.3 million
in H1 2014. The most recent reported sales are as follows:
U.S. $'m 2013 Q1 '14 Q2 '14 Q3 '14 Q4 '14 Q1 '15 Q2 '15
---------------------- ----- ------- ------- ------- ------- ------- -------
EXPAREL(R) net sales 76.1 34.4 44.9 50.2 59.0 56.0 56.9
---------------------- ----- ------- ------- ------- ------- ------- -------
The Group receives 3 percent of net sales (on a cash received
basis) of EXPAREL(R) . In addition, Skyepharma is eligible to
receive certain sales milestones. Pacira also announced that they
have initiated discussions with potential partners for EXPAREL(R)
outside the U.S.
On 16 April, Pacira announced that it had received a subpoena
from the U.S. Department of Justice requiring the production of a
broad range of documents related to marketing and promotional
practices for EXPAREL(R) . On 30 April, Pacira announced that,
given the current lack of visibility on EXPAREL(R) sales resulting
from the combined impact of recent regulatory developments and the
government investigation, it had decided not to give guidance for
sales of EXPAREL(R) for 2015. EXPAREL(R) sales in 2014 totalled
U.S. $188.5 million. Based on the latest net sales forecasts by
analysts covering Pacira, the Board now expects that the next sales
milestone of U.S. $8.0 million (GBP5.1 million), which is due when
annual net sales (on a cash received basis) reach U.S. $250
million, will be achieved in 2016.
On 28 May, Pacira announced it had completed the end-of-review
process with the U.S. Food and Drug Administration (FDA) regarding
its supplemental New Drug Application (sNDA) for the use of
EXPAREL(R) for administration as a nerve block to provide
postsurgical analgesia. Pacira plans to conduct additional Phase
III studies for upper extremity and lower extremity nerve blocks
that together would cover the majority of nerve blocks performed
today in the U.S. Pacira anticipates working with the FDA to
finalise the design of the Phase III trials and expects to initiate
the studies by the end of 2015. Pacira is also conducting clinical
studies for the product for oral surgical procedures and expects
these studies to be complete by early to mid-2016. If the clinical
studies are successful and approval is sought both the oral surgery
and nerve block indications could be approved and launched in
2017.
GSK Ellipta(R) products
Skyepharma's dry powder formulation technology is used in GSK's
new once-a-day treatments for asthma and COPD: Relvar(R)/Breo(R)
Ellipta(R), Anoro(R) Ellipta(R) and Incruse(R) Ellipta(R). The
Group has the potential for royalty income of up to GBP9.0 million
per annum from the license of the inhalation technologies.
On 30 April, GSK announced that the U.S. FDA had approved
Breo(R) Ellipta(R) (fluticasone furoate/vilanterol [FF/VI]) for the
once-daily treatment of asthma (but not for the relief of acute
bronchospasm) in patients aged 18 years and older. Breo(R)
Ellipta(R) has already been approved and launched by GSK in the
U.S. for COPD. On 29 July, GSK reported total Q2 2015 sales of
Breo(R) /Relvar(R) Ellipta(R) , Anoro(R) Ellipta(R) and Incruse(R)
Ellipta(R) of GBP70 million, up from GBP53 million in Q1 2015. The
most recent reported sales of these products are as follows:
GBP'm 2013 Q1 '14 Q2 '14 Q3 '14 Q4 '14 Q1 '15 Q2 '15
------------------------------ ----- ------- ------- ------- ------- ------- -------
Relvar(R) Ellipta(R)/Breo(R)
Ellipta(R) 8.3 2.9 10.9 15.4 38.0 40.4 53.3
------------------------------ ----- ------- ------- ------- ------- ------- -------
Anoro(R) Ellipta(R) - - 4.9 1.1 10.6 11.6 15.4
------------------------------ ----- ------- ------- ------- ------- ------- -------
Incruse(R) Ellipta(R) - - - - 0.1 1.0 1.0
------------------------------ ----- ------- ------- ------- ------- ------- -------
As of 30 June 2015, Relvar(R)/Breo(R) Ellipta(R) had been
approved in 68 countries for marketing and had been launched in 41
countries, including the U.S., Canada, UK, Germany and Japan. As of
the same date, Anoro(R) Ellipta(R) had been approved in 58
countries for marketing and had been launched in 27 countries,
including the U.S., UK, Germany and Japan. Incruse(R) Ellipta(R)
was launched in the UK in October 2014, in the U.S. in January 2015
and was approved in Japan in March 2015.
Research and Development
Skyepharma continues to seek to strengthen the product pipeline
through a mix of self-funded feasibility and technology development
projects with the potential for significant sales, and further
collaborations where partners fund the development on a time and
materials basis. Self-funded development projects include SKP-2075,
SKP-2076, SKP-1052 and work on oral drug delivery technologies, as
outlined below:
SKP-2075 is the first of a potential family of products being
developed to provide a new treatment for COPD. COPD affects an
estimated 210 million people worldwide and its treatment is
currently a U.S. $8.4 billion(1) market in the U.S., Japan and the
largest five E.U. countries.
In August 2014, the Group acquired (for no upfront
consideration) the global rights and related intellectual property
to a novel inhaled therapy platform from Pulmagen. Pulmagen and
Skyepharma believe that the use of ultra-low dose inhaled
theophylline to increase sensitivity to ICS could have applications
in a range of COPD products, including combinations which include
an ICS, especially for patients whose condition is inadequately
controlled by available therapies. The approach may also have
potential for certain patients with bronchial asthma.
Skyepharma is applying its proven expertise in inhaled drug
development to develop a first product (SKP-2075 - low dose
theophylline with ICS) to treat COPD. Good progress is being made
in formulating the product in preparation for a Phase II efficacy
and safety trial sized to produce clinically significant data. The
aim is to out-licence SKP-2075 to a pharmaceutical partner for
later-stage development and commercialisation. Skyepharma commenced
development of SKP-2075 in the second half of 2014 and aims to
complete the Phase II efficacy and safety trial in 2017. Initial
formulation has been carried out and preparations are being made
for pre-clinical work. The Group anticipates spending approximately
GBP14.0 million (depending on exchange rates), through
internally-generated funds, to develop SKP-2075 up to completion of
the Phase II trial. Under the terms of the acquisition, Pulmagen
will receive a share of Skyepharma's potential future revenues and
launch milestones from the successful exploitation of the acquired
platform.
(1) Chronic Obstructive Pulmonary Disease. Forecast.
Datamonitor, DMKC0047510, Publication Date: 03/10/2014
SKP-2076 is a novel inhalation product for a major respiratory
disease which combines known chemical entities. The Group commenced
feasibility work on this product in H1 2015 and is in discussions
with a potential partner about licensing the product for further
collaborative development.
SKP-1052 is a concept developed in-house which uses the Group's
proprietary Geoclock(TM) chronotechnology to reduce the risk of
severe nocturnal hypoglycaemia in insulin-treated patients with
type 1 and 2 diabetes mellitus. There is currently no recognised
medication to reduce the risk of this side-effect of insulin
treatment. Research undertaken by the Group indicates a significant
potential opportunity to treat over 1.2 million adult patients in
the U.S. alone.
Following the generation of supportive data in a proof of
concept study, the Group has received encouraging advice from the
FDA on the development plan and regulatory pathway in the U.S. for
SKP-1052 and is in discussion with potential partners to fund
further development.
Oral drug delivery technologies - work is also continuing on a
number of internally developed concepts for novel oral drug
delivery platform technologies. These include Soctec(TM), a concept
for a novel, proprietary gastro-retentive drug delivery platform
technology comprising a buoyant self-orienting capsule. After an
encouraging proof of concept study, further development is underway
to optimise the Soctec(TM) technology and to seek a partner for the
first feasibility project.
Collaborative development work
Activity continued during the period on development projects
largely funded by partners, including the development for
Mundipharma of the breath-actuated version of flutiform(R)
described above. Work on the development of new inhaled therapies
for COPD and severe asthma for RespiVert Ltd ("RespiVert"), a
subsidiary of Janssen Biotech, Inc., has declined as expected as
the projects transition to third parties to carry out later stage
development work.
Research and development expenditure
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
The Group's own investment in research and development (net of
any contribution margin from contract research and development for
third parties) increased to net expenditure of GBP2.0 million in H1
2015. This is due to work on the internal projects described above
to build the pipeline. In line with our January 2015 guidance, we
continue to forecast full year net expenditure of around GBP10
million and, therefore, the level of net investment is expected to
be substantially higher in the second half of the year.
Manufacturing and Supply
flutiform(R) supply chain
Under the agreements with Mundipharma and Kyorin, the Group is
responsible for arranging the manufacture and supply of
flutiform(R), and has contracted with Sanofi to manufacture and
assemble the product at its factory in Holmes Chapel, UK. The Group
has entered into agreements with a number of suppliers in order to
obtain materials required and have them supplied to Sanofi to
manufacture flutiform(R).
The Group has committed to substantial capital expenditure to
scale-up flutiform(R) production capacity. By 30 June 2015
cumulative capital expenditure was GBP17.5 million of which GBP0.6
million was incurred in H1 2015 (H1 2014: GBP0.9 million). In
addition, the Group incurred GBP0.9 million of product maintenance
costs in the first half (H1 2014: GBP1.4 million), which are
included as part of cost of sales. The Group will continue to
invest in:
-- working capital to support growth in supply volumes of
flutiform(R). As previously announced, longer supplier payment
terms to support the early development of the supply chain will
return to normal terms during H2 2015 and the impact of this on
working capital is approximately GBP4 million;
-- expenditure to maintain product supply (included in cost of
sales), forecast to be approximately GBP2 million for 2015; and
-- capital expenditure to increase production capacity to meet
anticipated growth in demand. In view of recent increases in
medium-term demand forecasts from customers, as announced in March
2015, capital investment in increasing capacity has been
accelerated when compared with previous plans and is now forecast
to be approximately GBP7 million to GBP8 million in 2015.
Lyon Facility
In 2011, Aenova leased the Group's manufacturing business and
premises in Lyon (together "the Facility") and is paying a rental
of EUR2.0 million (GBP1.4 million) per annum until the lease
arrangements expire in mid-2016. Aenova continues to manage and be
responsible for the operational and financial performance of the
Facility on a day-to-day basis. A site restructuring plan was
implemented in early 2015. The Group is reviewing options to add
additional work into the Facility ahead of the manufacturing
business reverting to Skyepharma when the lease terminates and is
planning some capital investments, mainly in 2016, with a view to
further improvements in operating efficiency and capabilities.
Consideration is also being given to negotiating an earlier date
for termination of the lease agreement.
The Facility currently manufactures seven Skyepharma products.
Five of these use the Geomatrix(TM) family of technologies:
Diclofenac-ratiopharm(R)-uno, Coruno(R), ZYFLO CR(R), Madopar DR(R)
and lower-dose formulations of Sular(R). LODOTRA(R)/RAYOS(R) uses
the Group's Geoclock(TM) chronotechnology. The other oral product,
Triglide(R), uses some of Skyepharma's solubilisation technology.
The Facility has current good manufacturing practice ("cGMP")
status, with approvals, amongst others, from the European Medicines
Agency, U.S. FDA, ANVISA (Brazil) and KFDA (South Korea). In June
2015, a routine FDA inspection of the Facility was successfully
concluded without any form 483 notices (observations for corrective
actions) being issued.
Other Approved Products
Solaraze(R) - combined U.S. sales of Solaraze(R) and its
authorised generic in the first half of 2015 as reported by the
Group's U.S. license partner Fougera Pharmaceuticals Inc., (part of
Sandoz), were significantly ahead of expectations due to
manufacturing issues at a competitor. Combined net sales of
Solaraze(R) in the U.S. in H1 2015 were U.S. $28.1 million (GBP18.5
million), up 73 percent compared with H1 2014. Skyepharma is
currently eligible for a royalty of 20 percent on net sales of
these products, which will reduce to a low-teens percentage once
all relevant licensed patents expire in Q3 2015. Net invoiced sales
in H1 2015 by Almirall, the Group's partner in Europe and certain
other territories, increased by 8 percent to EUR19.6 million
(GBP14.4 million).
Requip(R) Once-a-day - net sales of Requip(R) in H1 2015 as
reported by GSK totalled GBP45 million, a decrease of 17 percent
from H1 2014 (GBP54 million). This includes sales of other
formulations of Requip(R) on which the Group does not receive
royalties. Of the total sales, GBP14 million were generated in
Europe, a decrease of 36 percent, and GBP31 million arose in the
rest of the world, a decrease of 6 percent.
Xatral(R) OD (Uroxatral(R) in the U.S.) - Net sales of Xatral(R)
OD and Uroxatral in H1 2015, excluding the U.S., were EUR37.4
million (GBP27.1 million), compared with EUR36.4 million (GBP29.9
million) in H1 2014. Significant sales growth has been registered
mainly in China, Guatemala, Venezuela, Uruguay and Thailand.
Meanwhile sales of main Western European contributors such as
France and Italy have slightly decreased. In the U.S., net sales of
Uroxatral(R) for H1 2015 were EUR5.2 million (GBP3.8 million). In
H1 2014, sales were EUR4.0 million (GBP3.3 million).
Paxil CR(TM) - in H1 2015, net sales outside the U.S. were U.S.
$44.6 million (GBP29.2 million), compared with U.S. $52.4 million
(GBP31.3 million) in H1 2014.
LODOTRA(R) (RAYOS(R) in the U.S.) - Horizon reported combined
net sales of LODOTRA(R) and RAYOS(R) of U.S. $18.9 million (GBP12.4
million) in H1 2015 compared with net sales of U.S. $9.9 million
(GBP5.9 million) a year earlier. In April, a comprehensive effort
was initiated to provide more patients access to RAYOS through its
Prescription-Made-Easy(TM) program, which resulted in total
prescription growth versus the first quarter of 2015 of nearly 90
percent. Horizon recognises a significant portion of LODOTRA(R) and
RAYOS(R) sales at the time of delivery to its distribution partner,
Mundipharma, and those deliveries are not linear or related to
end-market sales in terms of timing and, therefore, can fluctuate
from year to year. The figures reported by Horizon are not the same
as the net sales used in the calculation of the royalties paid to
Skyepharma.
On July 15, 2013, the Group and Horizon received a Paragraph IV
Patent Certification from Watson Laboratories, Inc. - Florida
("WLF"), advising that WLF had filed an ANDA with the FDA for a
generic version of RAYOS(R). On August 26, 2013, a member of the
Group together with Horizon, filed suit against Watson, Actavis
Pharma, Inc., Andrx Corp., and Actavis, Inc., or collectively
"WLF". The lawsuit alleges that WLF has infringed certain patents
by filing an ANDA seeking approval from the FDA to market generic
versions of RAYOS(R) containing 1 mg, 2 mg, and 5 mg of prednisone
prior to the expiration of the patents. The subject patents are
listed in the FDA's Orange Book. The commencement of the patent
infringement lawsuit stays FDA approval of WLF's ANDA for 30 months
or until an earlier district court decision that the subject
patents are not infringed or invalid.
Madopar DR(R) (under the local brand name Prolopa DR(R) ) was
launched in Brazil by Roche in August 2015 for the treatment of
Parkinson's disease, bringing key product launches since March 2012
to nine (31 December 2014: eight) where the Group is eligible to
earn revenues.
Strategy
Skyepharma's strategy is to meet the needs of patients through
the application of its scientific know how and innovative
inhalation and oral drug delivery technologies. The Group aims to
grow revenues from its extensive portfolio of approved products and
ensure the success of its pipeline of product candidates. The Board
is looking to leverage its growing underlying profitability by
measured investment in developing new products and technologies
through a mix of own-funded development projects, collaborations
with partners and carefully targeted in-licensing transactions and
acquisitions. In inhalation, these could be aimed at the global
market for the treatment of asthma and/or COPD which is currently
worth U.S. $29.3 billion(2) per annum.
Typically, self-funded inhalation projects such as SKP-2075
would cost GBP10 million to GBP20 million over several years with
the aim of making the product suitable for out-licensing. Such
developments are likely to be novel products from early formulation
through to Phase II proof of concept. The Group's preferred
strategy is for early involvement of the eventual license partner,
to mitigate risk of any investment through to proof of concept.
Self-funded oral development projects are mainly focussed on
developing novel oral drug delivery technologies, such as
Soctec(TM), to proof of concept with a view to out-licensing the
technologies for use in partner-funded developments. Such oral
developments would typically cost GBP1 million to GBP2 million over
several years and additional amounts to develop manufacturing
processes to commercial scale. The Group may also consider
developing oral products to value inflexion points, especially to
exemplify new technologies, at a cost of approximately GBP3 million
to GBP5 million over several years. Such projects typically involve
early partnering before proof of concept to bring in relevant
therapy and late-stage development expertise even if much of the
development cost to that stage is funded by Skyepharma. Oral
products represent nearly half by value(3) of all prescriptions.
The Board's intention is to create a development pipeline with a
balance of own and partner-funded work where the average net annual
R&D investment could be up to 10-15 percent of sales, which is
a level which the Board believes will
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
still maintain growing profitability.
Whilst there is significant growth potential from the extensive
portfolio of approved products, Skyepharma also aims to strengthen
its product pipeline through carefully targeted acquisitions.
Ideally, these would typically be near-term earnings accretive,
though smaller acquisitions will also be considered where they
strengthen the Group's pipeline, technology or capabilities and
provide a good fit with the existing business.
(2) Company analysis based on: i) Chronic obstructive pulmonary
disease. Forecast. Datamonitor, DMKC0047510, Publication Date:
03/10/2014; ii) Asthma. Forecast, DMKC0082148, Publication Date:
18/06/2014; and iii) Extrapolation of main market sales to global
sales numbers with a factor of 25%.
(3) Company analysis based on Benchmarking the Pharmaceutical
Market by Drug Delivery to 2014: R&D / Drug Delivery,
Datamonitor, DMKC0062616, Publication Date 18/05/12
Key Performance Indicators
The Board considers the following Key Performance Indicators
("KPIs") to be the most relevant to the Group's operations:
Key financial performance indicators 2011 2012 2013 2014 H1 2014 H1 2015
-------------------------------------- ------ ----- ----- ----- ----- -------- --------
Revenue excluding milestones GBPm 49.1 42.2 56.9 64.7 26.9 40.7
-------------------------------------- ------ ----- ----- ----- ----- -------- --------
Signing and milestone payments
received (including receipts
related to EXPAREL(R) ) GBPm 5.7 12.5 5.5 9.2 2.7 0.1
-------------------------------------- ------ ----- ----- ----- ----- -------- --------
Gross research and development
expenditure GBPm 16.8 11.9 10.8 12.1 5.3 6.3
-------------------------------------- ------ ----- ----- ----- ----- -------- --------
Net investment in research
and development GBPm 8.0 2.4 0.5 3.8 1.8 2.0
-------------------------------------- ------ ----- ----- ----- ----- -------- --------
Liquidity GBPm 16.0 17.2 17.3 32.4 27.0 52.6
-------------------------------------- ------ ----- ----- ----- ----- -------- --------
Number of approved and marketable
revenue-generating products 12 13 15 16 15 16
---------------------------------------------- ----- ----- ----- ----- -------- --------
Description of KPIs
Revenue excluding milestones
Revenue excluding milestones reports revenues without the effect
of signing and milestone payments which by their nature tend to be
uneven and vary from one year to the next. This KPI shows
underlying revenue trends for royalties, contract research and
development work and supply activities. Revenue excluding
milestones in H1 2015 of GBP40.7 million is higher than H1 2014,
primarily due to the growth of flutiform(R) royalties and supply
revenues, EXPAREL(R) resulting in an increase in income from share
of net sales and royalties from the GSK Ellipta(R) products as well
as from Solaraze(R) in the U.S.
Signing and milestone payments received
This shows amounts of cash received for milestones in respect of
products and pipeline product candidates. The total cash received
during H1 2015 of GBP0.1 million is lower than the H1 2014 receipts
which primarily consisted of the EUR3.0 million (GBP2.5 million at
the time) payment in March 2014 from Mundipharma following the
launch of flutiform(R) in France.
Total research and development expenditure
Research and development expenditure measures the costs,
including direct and indirect overheads, of all research and
development activities. A breakdown of the costs during H1 2015 is
shown in Note 6: Research and development expenses. The expenditure
in H1 2015 is higher than the prior year due to the work which has
commenced on internal projects.
Net investment in research and development expenditure
This shows the Group's total research and development
expenditure net of costs reimbursed by development partners. It
shows that the Group's own investment in research and development
(net of any contribution margin from contract research and
development for third parties) increased to net expenditure of
GBP2.0 million in H1 2015. This is due to work on internal projects
to build the pipeline and is expected to accelerate further in the
second half of the year, in line with the guidance on full year net
expenditure given in January 2015 of around GBP10 million.
Liquidity
This measures the availability of cash resources for corporate
purposes. Liquidity as at 30 June 2015 consisted of cash and cash
equivalents of GBP27.6 million plus undrawn committed credit
facilities of GBP25 million.
Number of approved and marketable revenue-generating
products
This represents the number of products on which the Group does
or expects to earn revenues and which were approved for marketing
in at least one country at the end of the period. During 2014, the
total increased to 16 following the approval of Incruse(R) in the
E.U. and the U.S.
FINANCIAL REVIEW
The results for the six months ended 30 June 2015 reflect strong
growth in revenues, primarily from flutiform(R) royalty and supply,
share of net sales of EXPAREL(R) and growth in royalties from the
GSK Ellipta(R) products as well as from Solaraze(R) in the U.S.
Revenue
Revenues for the six months ended 30 June 2015 were GBP40.8
million (H1 2014: GBP34.4 million) comprising signing and milestone
receipts, contract research and development, royalties, product
supply, share of sales of EXPAREL(R) and rental income from the
Lyon Facility. The increase from 2014 is due to strong growth in
flutiform(R) royalty and supply revenues, the Group's share of
higher net sales of EXPAREL(R) , royalties from increased sales of
the GSK Ellipta(R) products and higher than expected royalties from
Solaraze(R) in the U.S. This is despite GBP7.5 million of
milestones largely from flutiform(R) and EXPAREL(R) , being
reported in the prior period. Underlying recurring revenue
excluding milestones was GBP40.7 million, some 51 percent higher
than H1 2014.
Revenue recognised from signing and milestone payments was
GBP0.1 million in H1 2015, which was down from the GBP7.5 million
reported for H1 2014. The prior period included the first
sales-related milestone of U.S. $8.0 million (GBP4.7 million) in
respect of EXPAREL(R) and a EUR3.0 million (GBP2.5 million)
milestone following the launch of flutiform(R) in France.
Contract research and development revenue increased by 23
percent to GBP4.3 million in H1 2015 (H1 2014: GBP3.5 million)
reflecting additional work for Mundipharma on the breath-actuated
version of flutiform(R) and work for RespiVert.
Royalty income was GBP10.8 million in H1 2015, GBP2.4 million
higher than in H1 2014, representing an increase, at constant
exchange rates, of 29 percent. Royalties from flutiform(R)
benefited from a first full six months of sales in Japan of the
120-puff version of the product following the December 2014 launch.
There was also strong in-market sales growth across the other
countries, boosted by the launch in Spain in December 2014. As
previously disclosed, the total product supply and royalty cost to
Mundipharma is capped at 35 percent of its net sales of
flutiform(R) , and at current supply prices this has the effect of
further reducing the net percentage royalty receivable as the
product is launched in lower priced markets. However, this further
reduction has been more than offset by a higher margin on product
supply. Royalty receipts were higher from the Ellipta(R) range of
products as GSK have reported growing sales, and also from
Solaraze(R) in the U.S. which has benefited from manufacturing
issues at a competitor.
Product supply revenue totalled GBP22.7 million in H1 2015 (H1
2014: GBP12.9 million), representing an increase of 97 percent at
constant exchange rates, reflecting the growth in sales of
flutiform(R) in the multiple markets, including the major European
markets together with both 56-puff and 120-puff versions of the
product in Japan. Based on forecasts received from partners, the
Board expects that revenues from the supply of flutiform(R) will be
an increasing proportion of the Group's revenues in the next few
years.
Other revenue of GBP2.9 million in H1 2015 (H1 2014: GBP2.1
million) comprises the Group's three percent share of Pacira's cash
receipts from net sales of EXPAREL(R) in the U.S. and rental income
from the Lyon Facility. Growth of other revenue over the prior year
is due to a higher share of sale income due to increased net sales
of EXPAREL(R) .
Cost of sales
Cost of sales increased to GBP18.9 million (H1 2014: GBP13.2
million) due to increased supplies of flutiform(R) and other
products. Gross margin from flutiform(R) product supply was 24
percent (H1 2014: 8 percent), benefiting from volume-related
supplier price breaks. The flutiform(R) supply chain is becoming an
increasingly important part of the Group's revenues. With higher
orders for flutiform(R), half year-end inventories increased to
GBP12.9 million (H1 2014: GBP11.1 million), which includes GBP3.0
million of capitalised overheads (H1 2014: GBP1.7 million). During
H1 2015 the flutiform(R) supply chain recorded a gross profit of
GBP4.5 million (H1 2014: GBP0.8 million).
Research and development
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
Gross investment in research and development in 2015 increased
to GBP6.3 million from GBP5.3 million in H1 2014 with contract
development revenues increasing to GBP4.3 million from GBP3.5
million in H1 2014. As a result, net investment in research and
development (expenses, net of contract development revenues) was
GBP2.0 million, compared with GBP1.8 million in H1 2014. This
reflects an increase in own-funded projects. Higher contract
development revenues are due to increased activity on
partner-funded projects, notably supporting the development of the
breath-actuated version of flutiform(R) for Mundipharma whilst work
for RespiVert on its new therapies for severe asthma and COPD has
reduced as anticipated and noted earlier.
Finance costs
Interest costs totalled GBP1.0 million (H1 2014: GBP5.3 million)
and consisted of GBP0.7 million (H1 2014: GBP1.4 million) in
respect of the CRC Finance facility (including a make-whole charge
of GBP0.3 million on early repayment), GBP0.2 million costs in
respect of establishing the RCF (H1 2014: nil), GBP0.1 million (H1
2014: GBP0.2 million) on other bank borrowings and GBPnil (H1 2014:
GBP3.7 million) in respect of the Bonds.
Foreign exchange
Foreign exchange consists of net translation gains and losses on
borrowings and cash denominated in a currency other than the
entity's functional currency. In H1 2015 this amounted to a loss of
GBP1.3 million (H1 2014: GBP0.1 million loss).
Operating profit and profit before tax
Operating profit in H1 2015 was GBP12.5 million (H1 2014:
GBP13.2 million).
Profit before tax for H1 2015 was GBP10.5 million (H1 2014:
GBP18.1 million loss). The prior year loss includes exceptional
financing costs of GBP25.5 million related to the capital raise and
bond repayment.
Taxation
The Group continues to recognise a deferred tax asset of GBP1.5
million (December 31 2014: GBP2.0 million). This reflects a prudent
assessment that a portion of the Swiss and U.S. tax losses will be
utilised in 2015 given the improving outlook for future
profitability. The remaining relevant Swiss tax losses are expected
to expire at the start of 2016. Following this, the rate of tax on
Swiss profits is expected to be a low teens percentage depending on
the mix of revenue streams. Income in the U.S. (principally in
relation to EXPAREL(R)) was largely offset by expiring tax losses
and intercompany interest in 2014 and is expected to be taxed at a
circa 25 percent effective rate in 2015 rising to circa 35 percent
effective rate through 2017 as the interest deduction reduces.
These rates are subject to any changes in tax legislation in the
relevant jurisdictions.
Net result
Profit for H1 2015 after exceptional items and taxation was
GBP9.1 million (H1 2014: GBP17.7 million loss).
Earnings per share
For H1 2015, basic earnings per share were 8.7 pence per share
and diluted earnings per share were 8.6 pence per share.
For the six months ended 30 June 2015, the difference between
the basic and diluted earnings per share amounts due to the
dilutive impact of the employee share awards on an IAS 33 earnings
per share basis as at 30 June 2015 was 1 pence per share.
For the period ended 30 June 2014 there were no differences
between the basic and diluted loss per share amounts since the
results were losses.
As at 30 June 2015 there were 104,812,259 Ordinary Shares in
issue (30 June 2014: 104,812,259).
In addition, as at 30 June 2015 there were the following
potential obligations to issue Ordinary Shares:
Description Maximum number Exercise price Expiry
of Ordinary Shares (per share)
------------------------------------------------ -------------------- -------------------- ------------
Deferred Consideration (Krypton) 375,000 GBP49.10 increasing No expiry
at 10% per annum
------------------------------------------------ -------------------- -------------------- ------------
Employee share matching scheme 20,218 Nil Three years
------------------------------------------------ -------------------- -------------------- ------------
Employee Long Term Incentive Plan share awards 2,892,822 Nil Three years
------------------------------------------------ -------------------- -------------------- ------------
Total at 30 June 2015 3,288,040
------------------------------------------------ -------------------- -------------------- ------------
Total at 30 June 2014 2,851,750
------------------------------------------------ -------------------- -------------------- ------------
The Directors believe that the options in respect of the
deferred consideration relating to the acquisition of Krypton in
1998 are unlikely to be exercised. This is because the exercise
price is very substantially above the prevailing market price of
shares in Skyepharma PLC and the exercise price increases by 10
percent per annum.
Further details on the refinancing, interest rates and other key
terms of the agreements can be found in Note 11: Earnings per
share
Cash position and liquidity
As at 30 June 2015 the Group had cash and cash equivalents of
GBP27.6 million (31 December 2014: GBP32.4 million). During H1
2015, the Group generated a cash inflow from operations of GBP9.2
million compared with an inflow of GBP8.8 million in H1 2014. Prior
year cash inflow from operations included GBP2.7 million milestone
receipts (H1 2015: GBP0.1 million).
In H1 2015 the Group's total cash outflow in respect of capital
expenditure was GBP1.3 million (H1 2014: GBP1.2 million) mainly
comprising the continued investment in scale up of flutiform(R)
manufacturing capacity, support for R&D activities and IT
improvement projects.
In H1 2015 the Group met scheduled financing commitments
comprising GBP0.8 million of net interest paid (H1 2014: GBP1.6
million) primarily relating to the CRC finance and the property
mortgages. During the period the Group also redeemed and terminated
early the remaining CRC Finance facility and the secured amortising
Swiss bank loan at a total cost of GBP11.4 million including an
early settlement amount of GBP0.4 million, saving GBP1.0 million in
future finance costs.
At 30 June 2015 Skyepharma had liquidity of GBP52.6 million (31
December 2014: GBP32.4 million) consisting of cash of GBP27.6
million and undrawn committed facilities of GBP25.0 million.
Net cash
The Group's total net cash, measured in accordance with IFRS,
comprises:
30 June 2015 31 December 2014
GBPm GBPm
------------------------------- ------------ ----------------
CRC Finance - (9.7)
Property mortgage (6.7) (6.6)
Bank borrowings - (1.1)
Total Debt (6.7) (17.4)
------------------------------- ------------ ----------------
Less cash and cash equivalents 27.6 32.4
------------------------------- ------------ ----------------
Net Cash position 20.9 15.0
------------------------------- ------------ ----------------
Non-current borrowings amounted to GBP4.9 million at 30 June
2015 (31 December 2014: GBP11.8 million), consisting of a property
mortgage secured on the land and buildings of Skyepharma AG.
Further details on the refinancing, interest rates and other key
terms of the agreements can be found in Note 13: Borrowings.
Balance Sheet
At 30 June 2015, the consolidated balance sheet shows total
shareholders' equity of GBP36.5 million (December 31 2014: GBP27.2
million).
Deferred Income
Part of an initial upfront milestone of EUR15.0 million (GBP10.1
million at the time) and additional funding by Mundipharma in
respect of the development of a high strength version of
flutiform(R) has been recorded in deferred income in the Group's
balance sheet and will be recognised in the Group's income
statement as the recoverable costs are recovered by Mundipharma by
deduction from royalties and sales-related milestones. As at 30
June 2015, this amounted to GBP9.5 million.
Non-current assets marketed for sale
One of the sites in Switzerland has been marketed for sale since
January 2011. As at 30 June 2015, the net book value of the site
was GBP4.1 million and was recorded in the Group's balance sheet
under assets held for sale, of which GBP3.9 million relates to land
and buildings and GBP0.2 million relates to laboratory and
manufacturing equipment.
In October 2014, a substantial part of this site was leased to
the Aenova Group for a period of 10 years and two months at an
initial rental of CHF0.5 million (GBP0.3 million) per annum, which
is subject to upwards-only review each year in line with the Swiss
consumer price index. Management believes that the existence of a
long-term lease will significantly improve the marketability of the
site to an investor as it brings the security of a long-term income
stream from a reputable tenant. An external property valuation
received in 2014 has provided Management with an indicative fair
value of the Swiss site that exceeds its carrying value. In
accordance with IFRS 5 Non-current assets held for sale no
depreciation or impairment has been recorded on this site during
the period.
Commitments
The Group has certain minimum commitments to a supplier in
respect of flutiform(R) which total approximately EUR2.9 million
(GBP2.0 million) for the remainder of 2015.
Going concern
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
At the time of approving the financial statements the Directors
have a reasonable expectation that the Company and the Group have
adequate resources to continue in operational existence for the
foreseeable future. Thus they continue to adopt the going concern
basis of accounting in preparing the Half Year Report 2015.
Foreign exchange risks
Almost all of the Group's operations are based in Continental
Europe and licence royalty payments are typically denominated in
various currencies, with sales-related payments based on underlying
sales in local currencies. This gives rise to direct and indirect
exposures to changes in foreign exchange rates notably the U.S.
Dollar, Euro and Swiss Franc. To minimise the impact of any
fluctuations, the Group's policy is to maintain natural hedges by
relating the structure of borrowings to the underlying trading cash
flows that generate them. Exchange translation gains and losses
relating to funding (cash and debt) are included in foreign
exchange gain or loss on net debt, other realised exchange gains
and losses and exchange translation gains and losses are included
within the revenue or expense line to which they most closely
relate. Where subsidiaries are funded centrally, this is achieved
by the use of long-term intercompany loans. Where settlement of
such intra-group loans is neither planned nor likely to occur in
the foreseeable future, they are treated as part of the net
investment and exchange differences are taken to reserves. No use
was made of currency options and forward currency contracts during
2015 to date or in 2014.
Forward looking statements
The foregoing disclosures contain certain forward-looking
statements. Although Skyepharma believes that the expectations
reflected in these forward-looking statements are reasonable, it
can give no assurance that these expectations will materialise.
Because the expectations are subject to risks and uncertainties,
actual results may vary significantly from those expressed or
implied by the forward-looking statements based upon a number of
factors. Such forward-looking statements include, but are not
limited to, the timescales for approval, launch or regulatory
filings for flutiform(R) and other products, the statements under
"Outlook", prospects and any forecast sales of flutiform(R) and
other products, the development of new products, risks related to
obtaining and/or maintaining regulatory approval for existing, new
or expanded indications of existing and new products, risks related
to Skyepharma's ability or that of its sub-contractors and partners
to manufacture products on a large scale or at all, risks related
to Skyepharma's and its marketing partners' ability to market
products on a large scale to maintain or expand market share in the
face of changes in customer requirements, competition and
regulatory and technological change, risks related to the ownership
and use of intellectual property, risks related to Skyepharma's
ability to manage growth, and the risk of costs associated with the
termination of the lease of the Lyon Facility in June 2016.
Skyepharma undertakes no obligation to revise or update any forward
statement to reflect events or circumstances after the date of this
Interim Report.
RESPONSIBILITY STATEMENT
The Directors of Skyepharma, as listed on pages 36 and 37 of the
2014 Annual Report and Accounts, confirm that to the best of their
knowledge:
a) The condensed set of financial statements have been prepared
in accordance with International Accounting Standards 34 Interim
Financial Reporting, as required by the Disclosure and Transparency
Rules ("DTR") 4.2.2;
b) The condensed set of financial statements, which have been
prepared in accordance with the applicable set of accounting
standards, gives a true and fair view of the assets, liabilities,
financial position and profit or loss of the issuer, or the
undertakings included in the consolidation as a whole as required
by the DTR 4.2.4;
c) The interim management report includes a fair review of the
information required by the DTR 4.2.7 - an indication of important
events which have occurred during the first six months of the year,
and a description of the principal risks and uncertainties for the
remaining six months of the year; and
d) The interim management report includes a fair review of the
information required by the DTR 4.2.8 - the disclosure of related
party transactions occurring during the first six months of the
year, and any changes in related party transactions disclosed in
the 2014 Annual Report and Accounts.
By order of the Board
Peter Grant
Chief Executive Officer
25 August 2015
CONDENSED CONSOLIDATED INCOME STATEMENT
For the six months ended 30 June 2015
Unaudited Unaudited Audited
6 months ended 30 June 2015 6 months ended Year ended
30 June 2014 31 December 2014
Notes GBPm GBPm GBPm
----------------------------------------- ------ ----------------------------- ---------------- ------------------
Revenue 4 40.8 34.4 73.8
Cost of sales 5 (18.9) (13.2) (32.9)
----------------------------------------- ------ ----------------------------- ---------------- ------------------
Gross profit 21.9 21.2 40.9
----------------------------------------- ------ ----------------------------- ---------------- ------------------
Selling, marketing and distribution
expenses (0.7) (0.7) (1.5)
Research and development expenses 6 (6.3) (5.3) (12.1)
Corporate costs (1.8) (1.5) (3.5)
Amortisation of intangible assets (0.4) (0.4) (0.8)
Share-based payment charge (0.4) (0.3) (0.5)
Other income 0.2 0.2 0.2
----------------------------------------- ------ ----------------------------- ---------------- ------------------
Pre-exceptional operating profit 12.5 13.2 22.7
----------------------------------------- ------ ----------------------------- ---------------- ------------------
Exceptional costs 7 - - (1.1)
----------------------------------------- ------ ----------------------------- ---------------- ------------------
Operating profit 12.5 13.2 21.6
----------------------------------------- ------ ----------------------------- ---------------- ------------------
Finance costs:
Interest 8 (1.0) (5.3) (7.0)
Exceptional finance cost 7 - (25.5) (25.5)
Foreign exchange (loss)/gain on net debt 9 (1.1) (0.4) 0.6
Finance income:
Revaluation gain/(loss) 0.1 (0.1) 0.4
Profit/(loss) before tax 10.5 (18.1) (9.9)
----------------------------------------- ------ ----------------------------- ---------------- ------------------
Income tax (charge)/credit 10 (1.4) 0.4 (0.6)
----------------------------------------- ------ ----------------------------- ---------------- ------------------
Total profit/(loss) for the period
attributable to the parent 9.1 (17.7) (10.5)
----------------------------------------- ------ ----------------------------- ---------------- ------------------
All results are derived from continuing operations.
The notes to the Condensed Consolidated Financial Statements
form an integral part of these Half Year Financial Statements.
CONDENSED CONSOLIDATED INCOME STATEMENT (CONTINUED)
For the six months ended 30 June 2015
Unaudited Unaudited Audited
6 months 6 months Year ended
Notes ended 30 ended 30 31 December
June 2015 June 2014 2014
Earnings per share for the period
Basic 11 8.7p (27.0)p (12.3)p
Diluted 11 8.6p (27.0)p (12.3)p
----------------------------------- -------- ----------- ----------- -------------
Pre-exceptional earnings per
share for the period
Basic 11 8.7p 11.8p 18.8p
Diluted 11 8.6p 11.8p 18.5p
----------------------------------- -------- ----------- ----------- -------------
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
The notes to the Condensed Consolidated Financial Statements
form an integral part of these Half Year Financial Statements.
CONDENSED CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE
INCOME/(EXPENSE)
For the six months ended 30 June 2015
Unaudited Unaudited Audited
6 months ended 6 months ended Year ended
30 June 2015 30 June 2014 31 December 2014
GBPm GBPm GBPm
-------------------------------------------------------------- ---------------- ---------------- ------------------
Profit/(loss) for the period 9.1 (17.7) (10.5)
Other comprehensive (expense)/income for the period, net of
tax:
Exchange differences on translation of foreign operations (0.2) 0.3 (0.5)
Net other comprehensive (expense)/income to be reclassified
to profit or loss in subsequent
periods (0.2) 0.3 (0.5)
Items not to be reclassified to profit or loss in subsequent
periods
Remeasurement of defined
benefit plans - - (2.0)
Net other comprehensive expense not being reclassified to
profit or loss in subsequent periods - - (2.0)
-------------------------------------------------------------- ---------------- ---------------- ------------------
Total other comprehensive (expense)/income for the period,
net of tax (0.2) 0.3 (2.5)
-------------------------------------------------------------- ---------------- ---------------- ------------------
Total comprehensive income/(expense) for the period
attributable to the owners of the parent,
net of tax 8.9 (17.4) (13.0)
-------------------------------------------------------------- ---------------- ---------------- ------------------
The notes to the Condensed Consolidated Financial Statements
form an integral part of these Half Year Financial Statements.
CONDENSED CONSOLIDATED BALANCE SHEET
As at 30 June 2015
Unaudited Unaudited Audited
As at As at As at
30 June 2015 30 June 2014 31 December 2014
Notes GBPm GBPm GBPm
---------------------------------- ------ -------------- -------------- ------------------
ASSETS
Non-current assets
Intangible assets 6.9 5.7 6.1
Property, plant and equipment 21.0 26.8 21.6
Other financial assets 13 0.5 - -
28.4 32.5 27.7
Current assets
Inventories 12 12.9 11.1 10.4
Trade and other receivables 14.7 18.5 14.6
Cash and cash equivalents 27.6 26.3 32.4
Other financial assets 13 0.1 - -
Deferred tax asset 10 1.5 2.5 2.0
56.8 58.4 59.4
---------------------------------- ------ -------------- -------------- ------------------
Non-current assets held for sale 14 4.1 - 3.9
---------------------------------- ------ -------------- -------------- ------------------
Total assets 89.3 90.9 91.0
---------------------------------- ------ -------------- -------------- ------------------
LIABILITIES
Current liabilities
Trade and other payables (29.1) (23.9) (29.3)
Borrowings 13 (1.8) (8.7) (5.6)
Deferred income (2.8) (1.8) (3.0)
Provisions 15 (0.5) - (1.1)
---------------------------------- ------ -------------- -------------- ------------------
(34.2) (34.4) (39.0)
Non-current liabilities
Other borrowings 13 (4.9) (20.5) (11.8)
Deferred income (6.7) (9.3) (6.9)
Pension liability 15 (6.1) (4.0) (5.9)
Provisions 15 (0.9) (0.1) (0.2)
(18.6) (33.9) (24.8)
---------------------------------- ------ -------------- -------------- ------------------
Total liabilities (52.8) (68.3) (63.8)
---------------------------------- ------ -------------- -------------- ------------------
Net assets 36.5 22.6 27.2
---------------------------------- ------ -------------- -------------- ------------------
SHAREHOLDERS' EQUITY
Share capital 16 179.4 179.4 179.4
Share premium 407.2 407.2 407.2
Translation reserve (25.7) (24.7) (25.5)
Own share reserve (0.1) (0.1) (0.1)
Share based payments reserve 1.2 - -
Retained losses (534.5) (548.2) (542.8)
Other reserves 9.0 9.0 9.0
---------------------------------- ------ -------------- -------------- ------------------
Total shareholders' equity 36.5 22.6 27.2
---------------------------------- ------ -------------- -------------- ------------------
The notes to the Condensed Consolidated Financial Statements
form an integral part of these Half Year Financial Statements.
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the six months ended 30 June 2015
Attributable to owners of the parent
Share Share Translation Own share Share Retained Other Total
capital premium reserve reserve based losses reserves shareholders'
payments equity
GBPm GBPm GBPm GBPm GBPm GBPm GBPm GBPm
----------------- --------- --------- ------------ ---------- ---------- --------- ---------- ----------------
As at 1 January
2015 179.4 407.2 (25.5) (0.1) - (542.8) 9.0 27.2
Profit for
the period - - - - - 9.1 - 9.1
Other
comprehensive
expense - - (0.2) - - - - (0.2)
----------------- --------- --------- ------------ ---------- ---------- --------- ---------- ----------------
Total
comprehensive
income for
the period - - (0.2) - - 9.1 - 8.9
Share-based
payment charge - - - - 0.4 - - 0.4
Other movements:
transfer within
reserves - - - - 0.8 (0.8) - -
As at 30 June
2015 179.4 407.2 (25.7) (0.1) 1.2 (534.5) 9.0 36.5
----------------- --------- --------- ------------ ---------- ---------- --------- ---------- ----------------
Share based payment awards made under the 2012 LTIP scheme will
vest from March 2016 onwards and hence a share based payment
reserve has been presented separately within equity.
The notes to the Condensed Consolidated Financial Statements
form an integral part of these Half Year Financial Statements.
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
For the six months ended 30 June 2014
Attributable to owners of the parent
Share Share Translation Own share Retained Other reserves Total shareholders'
capital premium reserve reserve losses equity
GBPm GBPm GBPm GBPm GBPm GBPm GBPm
-------------------- --------- --------- ------------ ---------- --------- --------------- --------------------
As at 1 January
2014 120.7 361.7 (25.0) (0.2) (530.8) 9.0 (64.6)
Loss for the period - - - - (17.7) - (17.7)
Other comprehensive
income - - 0.3 - - - 0.3
-------------------- --------- --------- ------------ ---------- --------- --------------- --------------------
Total comprehensive
expense for the
period - - 0.3 - (17.7) - (17.4)
Issue of share
capital 58.7 53.3 - - - - 112.0
Costs associated
with Capital Raise - (7.8) - - - - (7.8)
Own shares acquired
during period - - - 0.1 - - 0.1
Share based payment
charge - - - - 0.3 - 0.3
As at 30 June 2014 179.4 407.2 (24.7) (0.1) (548.2) 9.0 22.6
-------------------- --------- --------- ------------ ---------- --------- --------------- --------------------
The notes to the Condensed Consolidated Financial Statements
form an integral part of these Half Year Financial Statements.
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For year ended 31 December 2014
Attributable to owners of the parent
Share Share Translation Own share Retained Other Total shareholders'
capital premium reserve reserve losses reserves equity
GBPm GBPm GBPm GBPm GBPm GBPm GBPm
--------------------- --------- --------- ------------ ---------- --------- ---------- --------------------
As at 1 January
2014 120.7 361.7 (25.0) (0.2) (530.8) 9.0 (64.6)
Loss for the year - - - - (10.5) - (10.5)
Other comprehensive
expense - - (0.5) - (2.0) - (2.5)
--------------------- --------- --------- ------------ ---------- --------- ---------- --------------------
Total comprehensive
expense for the
year - - (0.5) - (12.5) - (13.0)
Issue of share
capital 58.7 53.3 - - - - 112.0
Costs associated
with Capital Raise - (7.8) - - - - (7.8)
Other movements - - - 0.1 - - 0.1
Share-based payment
charge - - - - 0.5 - 0.5
As at 31 December
2014 179.4 407.2 (25.5) (0.1) (542.8) 9.0 27.2
--------------------- --------- --------- ------------ ---------- --------- ---------- --------------------
The notes to the Condensed Consolidated Financial Statements
form an integral part of these Half Year Financial Statements.
CONDENSED CONSOLIDATED CASH FLOW STATEMENT
For the six months ended 30 June 2015
Unaudited Unaudited Audited
6 months ended 6 months Year ended
30 June 2015 ended 31 December
30 June 2014 2014
Notes GBPm GBPm GBPm
---------------------------------------- ------ ---------------- -------------- -------------
Cash flow from operating activities
Cash generated by operations (a) 9.2 8.8 30.2
Income tax paid (0.6) (0.1) (0.3)
Net cash generated by operating
activities 8.6 8.7 29.9
Cash flow from investing activities
Purchases of property, plant and
equipment (0.4) (0.3) (1.1)
Purchases of intangible assets (0.9) (0.9) (1.8)
Interest received - - 0.1
Net cash used in investing activities (1.3) (1.2) (2.8)
Cash flow from financing activities
Repayment of borrowings (11.4) (3.8) (16.1)
Repayment of bonds (exceptional) - (95.6) (95.6)
Costs associated with repayment
of bonds (exceptional) - (0.4) (0.4)
Interest paid (0.8) (1.6) (3.2)
Issue of shares (exceptional) - 112.0 112.0
Costs associated with Capital Raise
(exceptional) - (7.8) (7.8)
Revolving Credit Facility issuance
costs 13 (0.5) - -
Net cash (used)/generated in financing
activities (12.7) 2.8 (11.1)
Effect of exchange rate changes 0.6 (0.5) (0.1)
---------------------------------------- ------ ---------------- -------------- -------------
Net (decrease) / increase in cash
and cash equivalents (4.8) 9.8 15.9
Cash and cash equivalents at beginning
of the year 32.4 16.5 16.5
Net (decrease)/increase in cash
and cash equivalents (4.8) 9.8 15.9
---------------------------------------- ------ ---------------- -------------- -------------
Cash and cash equivalents at end
of period 27.6 26.3 32.4
---------------------------------------- ------ ---------------- -------------- -------------
The notes to the Condensed Consolidated Financial Statements
form an integral part of these Half Year Financial Statements.
NOTES TO THE CONDENSED CONSOLIDATED CASH FLOW STATEMENT
For the six months ended 30 June 2015
(a) Cash generated by operations
Unaudited Unaudited Audited
6 months ended 6 months ended Year ended
30 June 2015 30 June 2014 31 December
2014
Notes GBPm GBPm GBPm
--------------------------------- ------ ---------------- ---------------- -------------
Profit/(loss) for the period 9.1 (17.7) (10.5)
Adjustments for:
Tax 1.4 (0.4) 0.6
Depreciation 1.3 1.0 2.6
Amortisation 0.4 0.4 0.8
Finance costs 8 1.0 5.3 6.0
Exceptional finance cost 7 - 25.5 25.5
Finance income 8 (0.1) - (0.1)
Share-based payment charge 0.4 0.3 0.5
Exchange losses/(gains) on
translation (0.4) 0.5 0.8
Exceptional operating cost 7 - - 1.1
Other non-cash charges (0.1) (0.1) (0.1)
--------------------------------- ------ ---------------- ---------------- -------------
Operating cash flows before
movements in working capital 13.0 14.8 27.2
Changes in working capital
(Increase) in inventories (2.1) (2.5) (1.8)
Decrease/(increase) in trade
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
and other receivables 0.5 (5.3) (1.4)
(Decrease)/increase in trade
and other payables (1.5) 2.2 7.7
(Decrease) in deferred income (0.7) (0.4) (1.5)
--------------------------------- ------ ---------------- ---------------- -------------
Cash generated by operations 9.2 8.8 30.2
--------------------------------- ------ ---------------- ---------------- -------------
The notes to the Condensed Consolidated Financial Statements
form an integral part of these Half Year Financial Statements.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1 General information
The Half Year Report of the Group for the six months ended 30
June 2015 ("Half Year Report 2015") was authorised for issue in
accordance with a resolution of the Directors on 25 August 2015.
The Half Year Report 2015 is unaudited but has been reviewed by the
Auditors as set out in their report.
Skyepharma PLC (the "Company") and its subsidiaries (together
the "Group") combines proven scientific expertise with validated
proprietary drug delivery technologies to develop innovative oral
and inhalation pharmaceutical products.
The Company is incorporated and domiciled in the United Kingdom,
with its registered office at 46-48 Grosvenor Gardens, London SW1W
0EB.
These condensed half-yearly financial statements are unaudited
and do not constitute statutory accounts of the Group as defined in
section 434 of the Companies Act 2006. The auditor, Ernst &
Young LLP, has carried out a review of the financial information in
accordance with the guidance contained in International Standard on
Review Engagements (UK and Ireland) 2410 - Review of Interim
Financial Information Performed by the Independent Auditor of the
Entity, and their review report is set out at the end of this
report.
The financial information for the year ended 31 December 2014
has been extracted from the Group's published financial statements
for that year, and a copy of the statutory accounts for that
financial year has been delivered to the Registrar of Companies.
The auditors reported on those accounts and their report was
unqualified, did not draw attention to any matters by way of
emphasis and did not contain a statement under section 498(2) or
(3) of the Companies Act 2006.
2 Accounting policies
(a) Basis of preparation
The interim condensed consolidated financial statements for the
six months ended 30 June 2015 have been prepared in accordance with
IAS 34 Interim Financial Reporting.
The interim condensed consolidated financial statements do not
include all the information and disclosures required in the annual
financial statements, and should be read in conjunction with the
Group's annual financial statements as at 31 December 2014.
The accounts have been prepared under the historic cost
convention. Historic cost is generally based on the fair value of
the consideration given in exchange for the assets.
Going concern
The Directors have, at the time of approving the financial
statements, a reasonable expectation that the Group has adequate
resources to continue in operational existence for the foreseeable
future. Thus they continue to adopt the going concern basis of
accounting in preparing the financial statements.
Significant accounting policies
The accounting policies, presentation and methods of computation
are as applied in the Group's 2014 Annual Report and Accounts. The
following standards and interpretations, relevant to the Group,
have been issued at the date of these accounts but are not yet
effective:
-- IFRS 9 Financial instruments - Classification and Measurement
-- IFRS 15 Revenue from contracts with customers
-- Annual Improvements to IFRSs 2012-2014
-- Disclosure Initiative (Amendments to IAS 1)
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
2 Accounting policies (continued)
The Group has adopted the following accounting policy during the
period ended 30 June 2015:
-- IAS 19 Defined Benefit Plans: Employee Contributions (Amendments to IAS 19)
-- Annual Improvements to IFRSs 2010-2012
-- Annual Improvements to IFRSs 2011-2013
Adoption of these standards did not have any effect on the
financial position of the Group, or result in changes in accounting
policy or additional disclosure.
3 Segmental reporting
The Board has identified, based on information used internally
by management to assess the performance of and allocate resources
to the business, that it has one operating segment being the
development and supply of pharmaceutical products.
4 Revenue by income stream
Unaudited Unaudited Audited
6 months ended 30 June 2015 6 months ended Year ended
GBPm 30 June 2014 31 December 2014
GBPm GBPm
--------------------------------------------- ----------------------------- ------------------ ------------------
Revenue earned is analysed as follows:
Signing and milestone payments 0.1 7.5 9.1
Contract research and development revenue 4.3 3.5 8.3
Royalties 10.8 8.4 17.2
Product supply 22.7 12.9 34.2
Other revenue 2.9 2.1 5.0
--------------------------------------------- ----------------------------- ------------------ ------------------
Total revenue 40.8 34.4 73.8
--------------------------------------------- ----------------------------- ------------------ ------------------
During the six months ended 30 June 2015, flutiform(R) generated
GBP2.5 million of contract development revenue (H1 2014: GBP1.3
million), GBP2.1 million of royalties (H1 2014: GBP1.5 million) and
GBP19.0 million in product supply revenues (H1 2014: GBP9.8
million).
Other revenue includes GBP2.2 million (H1 2014: GBP1.3 million)
from the Group's share of net sales of EXPAREL(R) in the United
States and GBP0.7 million (H1 2014: GBP0.8 million) in rental
income in respect of the lease to the Aenova Group of the Group's
manufacturing facility in Lyon, France.
5 Cost of sales
Unaudited Unaudited Audited
6 months ended 6 months ended Year ended
30 June 2015 30 June 2014 31 December 2014
GBPm GBPm GBPm
--------------------- ---------------- ---------------- ------------------
Product supply 18.5 12.8 32.3
Other cost of sales 0.4 0.4 0.6
--------------------- ---------------- ---------------- ------------------
Total cost of sales 18.9 13.2 32.9
--------------------- ---------------- ---------------- ------------------
During the six months ended 30 June 2015, cost of sales related
to the supply of flutiform(R) totalled GBP14.5 million (H1 2014:
GBP9.0 million).
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
6 Research and development expenses
Unaudited Unaudited Audited
6 months ended 6 months ended 30 June 2014 Year ended
30 June 2015 GBPm 31 December 2014
GBPm GBPm
------------------------------------------------- ---------------- ----------------------------- ------------------
Clinical trials, supplies and other external
costs directly recharged to development
partners 0.3 0.6 1.1
Other external clinical trial and supply costs 0.6 0.4 0.6
Other research and development costs 5.4 4.3 10.4
------------------------------------------------- ---------------- ----------------------------- ------------------
Total research and development expenses 6.3 5.3 12.1
------------------------------------------------- ---------------- ----------------------------- ------------------
7 Exceptional costs
Unaudited Unaudited Audited
6 months ended 6 months ended Year ended
30 June 2015 30 June 2014 31 December
GBPm GBPm 2014
GBPm
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
------------------------------------------- ----------------- ---------------- -------------
Exceptional operating costs
Lyon restructuring - - 1.1
------------------------------------------- ----------------- ---------------- -------------
Exceptional financing costs
Loss on extinguishment of bonds - 25.1 25.1
Costs related to bond repayment - 0.4 0.4
------------------------------------------- ----------------- ---------------- -------------
Total exceptional costs - financing items - 25.5 25.5
------------------------------------------- ----------------- ---------------- -------------
Total exceptional costs - 25.5 26.5
------------------------------------------- ----------------- ---------------- -------------
There were no exceptional items charged to the income statement
during the first six months of 2015 and the remaining provision as
at 30 June 2015 was GBP0.5m.
During 2014, the Aenova Group concluded consultations with the
Works Council in respect of a site restructuring plan for the
Facility in Lyon which was implemented in early 2015. Under the
arrangements with Aenova, some of the costs of the restructuring
were reimbursed by Skyepharma and accordingly a GBP1.1 million
exceptional operating cost was recognised in H2 2014.
The Capital Raise and bond repayment on 30 April 2014 resulted
in a GBP25.5 million exceptional finance cost during 2014 (of which
GBP25.1 million was non-cash) and was recorded under Exceptional
Items within the Income Statement as follows:
Audited
Year ended
Exceptional finance costs 31 December 2014
GBPm
------------------------------------ ------------------
Carrying amount of outstanding
bonds
as at 30 April 2014 70.5
Repayment:
- Face value of outstanding 2024
Bonds (60.8)
- Premium and accrued interest (34.8)
------------------------------------ ------------------
Total Repayment 95.6
------------------------------------ ------------------
Exceptional non-cash financing
charge (25.1)
Cash transaction costs of bond
repayment (0.4)
------------------------------------ ------------------
Total exceptional finance cost (25.5)
------------------------------------ ------------------
There was no tax effect of these exceptional costs for the year
ended 31 December 2014.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
8 Finance costs and income
Unaudited Unaudited Audited
6 months ended 6 months ended Year ended
30 June 2015 30 June 2014 31 December
GBPm GBPm 2014
GBPm
-------------------------- ---------------- ---------------- -------------
Finance cost - interest:
Bank borrowings 0.1 0.2 0.4
CRC finance 0.7 1.4 2.8
Refinancing costs 0.2 - 0.1
Bonds - 3.7 3.7
Total finance costs 1.0 5.3 7.0
-------------------------- ---------------- ---------------- -------------
Finance income in the period principally relates to GBP0.1
million of foreign exchange gains on the final repayment and
revaluation of the U.S. dollar CRC loan (refer to note 13) (30 June
2014: GBP0.1 million loss).
9 Foreign exchange on net debt
Unaudited Unaudited Audited
6 months ended 6 months ended Year ended
30 June 2015 30 June 2014 31 December 2014
GBPm GBPm GBPm
------------------------------------------------ ---------------- ---------------- ------------------
CRC finance 0.4 0.1 (0.9)
Foreign denominated cash balances (1.3) (0.1) 0.5
Intercompany loans (0.2) (0.5) 0.9
------------------------------------------------ ---------------- ---------------- ------------------
Total foreign exchange loss/(gain) on net debt (1.1) (0.5) 0.5
------------------------------------------------ ---------------- ---------------- ------------------
10 Taxation
Unaudited Unaudited Audited
6 months ended 6 months ended Year ended
30 June 2015 30 June 2014 31 December 2014
GBPm GBPm GBPm
------------------------------------------------------------- ---------------- ---------------- ------------------
Current tax:
Current income tax charge 0.8 0.1 0.6
Deferred tax charge/(credit):
Relating to origination and reversal of timing differences 0.6 (0.5) -
------------------------------------------------------------- ---------------- ---------------- ------------------
Income tax charge/(credit)
reported in the Income Statement 1.4 (0.4) 0.6
------------------------------------------------------------- ---------------- ---------------- ------------------
The Group is involved in worldwide operations and as such, its
overall effective tax rate is sensitive to the geographic mix of
profitability. The overall effective tax rate in the first half of
2015 was 13 percent reflecting a combination of higher tax rates in
the U.S. where the income from EXPAREL(R) arises, nil tax in
Switzerland due to utilisation of final brought forward expiring
tax losses where the majority of the Group's profit is generated
and nil tax in the UK where there is no income and substantial
brought forward tax losses. The utilisation of Swiss tax losses in
this period caused deferred tax movements that increased the
Group's effective tax rate.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
10 Taxation (continued)
The Finance Act 2014, which provides for a reduction in the main
rate of corporation tax from 23 percent to 21 percent effective
from 1 April 2014, was enacted on 3 July 2012. A further reduction
from 21 percent to 20 percent by 1 April 2015 was enacted on 2 July
2013. The Group balance sheet as at 30 June 2015 included a tax
payable liability of GBP0.5 million (31 December 2014 GBP0.8
million).
Deferred tax
The movement in deferred tax assets during the period is as
follows:
Deferred
tax assets
GBPm
-------------------------------------------------------- ------------
As at 1 January 2015 2.0
Utilised in the period:
UK -
Overseas (1.1)
Credited to the Income Statement:
UK -
Overseas 0.6
-------------------------------------- ------------------------------
As at 30 June 2015 1.5
-------------------------------------- ------------------------------
Deferred tax assets are recognised for tax loss carry-forwards
to the extent that the realisation of the related tax benefit
through reducing future taxation payable is probable. For the
interim period the Group taxation estimates are updated following
the results for the first half of 2015 and for subsequent estimates
of the future profits that will be chargeable to corporation
tax.
Full details of the Group's taxation position at December 2014
are provided in note 14 of the 2014 Annual report.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
11 Earnings per share
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
Earnings per share is calculated based on earnings after tax and
the weighted average number of Ordinary Shares in issue during the
period. For the six months ended 30 June 2015, the difference
between the basic and diluted earnings per share amounts due to the
dilutive impact of employee share awards as at 30 June 2015, and on
an IAS 33 earnings per share basis, was 1 pence per share. For the
periods ended 30 June 2014 and 31 December 2014 there were no
differences between the basic and diluted loss per share amounts
since the results were losses.
Unaudited Unaudited Audited
6 months ended 30 June 2015 6 months ended 30 June 2014 Year ended
31 December 2014
Earnings GBPm GBPm GBPm
---------------------------------- ----------------------------- ----------------------------- --------------------
Attributable profit before
exceptional items 9.1 7.8 16.1
Exceptional items - (25.5) (26.6)
---------------------------------- ----------------------------- ----------------------------- --------------------
Basic and diluted attributable
profit/(loss) after tax 9.1 (17.7) (10.5)
---------------------------------- ----------------------------- ----------------------------- --------------------
Number of shares Millions Millions Millions
---------------------------------- ----------------------------- ----------------------------- ------------------
Weighted average number of
Ordinary Shares in issue 104.8 65.7 85.3
Potentially dilutive share awards 1.5 - -
---------------------------------- ----------------------------- ----------------------------- --------------------
Weighted average number of
diluted Ordinary Shares 106.3 65.7 85.3
---------------------------------- ----------------------------- ----------------------------- --------------------
Basic and diluted earnings per Pence Pence Pence
Ordinary Share
---------------------------------- ----------------------------- ----------------------------- --------------------
Basic earnings per Ordinary Share 8.7 (27.0) (12.3)
Diluted earnings per Ordinary
Share 8.6 (27.0) (12.3)
---------------------------------- ----------------------------- ----------------------------- --------------------
Pre-exceptional earnings per share is as follows:
Number of shares Millions Millions Millions
----------------------------------------------------- --------- --------- ---------
Weighted average number of Ordinary Shares in issue 104.8 65.7 85.3
Potentially dilutive share awards 1.5 - 1.6
----------------------------------------------------- --------- --------- ---------
Weighted average number of diluted Ordinary Shares 106.3 65.7 86.9
----------------------------------------------------- --------- --------- ---------
Basic and diluted earnings per Ordinary Share Pence Pence Pence
----------------------------------------------------- --------- --------- ---------
Pre-exceptional
Basic earnings per Ordinary Share 8.7 (27.0) (12.3)
Diluted earnings per Ordinary Share 8.6 (27.0) (12.3)
----------------------------------------------------- --------- --------- ---------
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
12 Inventories
Unaudited Unaudited Audited
As at As at As at
30 June 2015 30 June 2014 31 December
GBPm GBPm 2014
GBPm
---------------------------- -------------- -------------- -------------
Inventories - flutiform(R) 12.9 11.1 10.4
---------------------------- -------------- -------------- -------------
During H1 2015, certain inventory was written down to net
realisable value resulting in a charge of GBP0.1 million (H1 2014
GBP0.1 million) to cost of sales.
13 Borrowings
Unaudited Unaudited Audited
As at As at As at
30 June 2015 30 June 2014 31 December
GBPm GBPm 2014
GBPm
------------------------------ -------------- -------------- -------------
Current
Bank borrowings - 1.3 1.1
Property mortgage 1.8 2.0 1.8
CRC finance - 5.4 2.7
Total current borrowings 1.8 8.7 5.6
Non-current
Property mortgage 4.9 4.9 4.8
CRC finance - 15.6 7.0
Total non-current borrowings 4.9 20.5 11.8
------------------------------ -------------- -------------- -------------
Total borrowings 6.7 29.2 17.4
------------------------------ -------------- -------------- -------------
Total debt has decreased by GBP10.7 million in the period. This
is due to the early repayment of U.S. Dollar portion of the CRC
finance facility and of the Bank borrowings, as well as scheduled
repayment of debt.
Bank borrowings
On 30 June 2015 the amortising loan with the
Basellandschaftliche Kantonalbank ("BLKB") of CHF1.8 million
(GBP1.2 million) was fully repaid ahead of the scheduled
termination date of 30 June 2018.
Property mortgages
In February 2011 the Group renewed its two mortgage agreements
with the BLKB. One of the sites in Switzerland was leased to Aenova
in October 2014. As at 30 June 2015, this site has a net book value
of CHF 6.1 million (GBP4.1 million) and a mortgage of CHF 2.4
million (GBP1.6 million) which will be repayable on completion of
any sale. This mortgage bears interest at a variable rate
(currently 4.0 percent) and is repayable with three months' notice
from either party.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)
13 Borrowings (continued)
As at 30 June 2015, the carrying value of the mortgage relating
to the buildings which are in use by the business is CHF 7.4
million (GBP4.9 million), which bears interest at a fixed 3.6
percent per annum and is fully repayable, if not extended, in
February 2016 at which point it will automatically roll into a
variable rate mortgage on an indefinite term cancellable by either
party on 3 months' notice. Such a roll over mortgage is common
market practise in Switzerland and the mortgage was previously
rolled over onto a new fixed interest term in both 2006 and 2011.
As it is Management's current intention to roll the mortgage over
in the same way, the mortgage is classified as long term.
CRC finance
The facility was terminated in February 2015, following the
repayment that month of the outstanding U.S. Dollar loan at a cost
of GBP10.5 million. The Euro portion of the loan was repaid in
October 2014 at a cost of GBP10.6 million. The key terms of the CRC
Facility (as amended) and the applicable interest rates are set out
within the 2014 Annual Report and Accounts. There were no
amendments made to the Facility during the period ended 30 June
2015.
Revolving Credit Facility ("RCF")
In April 2015, Skyepharma signed a GBP25 million five year
unsecured multi-currency RCF with Barclays Bank PLC. There is an
accordion option to extend the facility up to GBP35 million during
the five year term which ends in March 2020. At present GBPnil has
been drawn down against the facility.
Debt issue costs of GBP0.7 million, of which GBP0.5 million were
paid during H1 2015, were capitalised in April 2015 as other
financial assets. These are being amortised evenly to the income
statement over the five year term of the facility. A portion of
these costs may be allocated to future draw downs in accordance
with IAS 39 Financial instruments.
The cost of borrowing under the facility is 1.30 percent above
the relevant LIBOR/EURIBOR reference rate. There are two financial
covenants which will be tested at each reporting period if drawings
were made in the previous six months against the facility.
14 Non-current assets classified as held for sale
(MORE TO FOLLOW) Dow Jones Newswires
August 26, 2015 02:00 ET (06:00 GMT)
Skyepharma (LSE:SKP)
Historical Stock Chart
From Nov 2024 to Dec 2024
Skyepharma (LSE:SKP)
Historical Stock Chart
From Dec 2023 to Dec 2024
